We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The EMA commissioned the ACCESS project with Utrecht University in May to study data sources and methods that can be used for the postmarketing evaluation of COVID-19 vaccines. Read More
Acadia Pharmaceuticals’ Nuplazid (pimavanserin) failed to meet its primary endpoint in two phase 3 clinical trials evaluating it for major depressive disorder. Read More
Based on the results of a phase 2 trial, UK-based Synairgen said Monday that its antiviral SNG001 reduced the risk of severe disease in hospitalized COVID-19 patients. Read More
Preliminary data from a German phase 1/2 trial showed that Pfizer’s and BioNTech’s mRNA-based coronavirus vaccine candidate is safe and generated immune responses in participants, the companies announced Monday. Read More
In a first glimpse at the efficacy of a COVID-19 vaccine from AstraZeneca and the University of Oxford, highly anticipated clinical data found that it produces strong immune response. Read More